Johnson & Johnson’s top-selling prostate cancer treatment is facing a stiff challenger in Medivation’s Xtandi, but an acquisition may not be in the cards.
Johnson & Johnson’s top-selling prostate cancer treatment is facing a stiff challenger in Medivation’s Xtandi, but an acquisition may not be in the cards.